Hikma and Vectura make new application for GSK knock-off
Hikma and Vectura make new application for GSK knock-off. The generics giant and the inhaled medicines specialist have developed VR315US, a knock-off version of GlaxoSmithKline PLC’s (LON:GSK) top-selling asthma treatment, Advair Diskus, which generated sales of around US$1bn last year. The US Food and Drug Administration (FDA) last year rejected a previous application, requesting further data that the companies said has been added to the new submission after the completion of a clinical endpoint study. The drug will compete with GSK’s Advair as well as Wixela Inhub, another generic version launched in February 2019 by Dutch firm Mylan NV (NASDAQ:MYL) and UK partner Consort Medical PLC (LON:CSRT).